FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Stock Information for Forte Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Forte Biosciences Inc.

Forte Biosciences Announces Pricing of $150 Million Public Offering
Forte Biosciences Announces Proposed Public Offering
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.